Zobrazeno 1 - 10
of 65
pro vyhledávání: ''
Autor:
Miguel Gil-Gil, José A. García-Sáenz, E Dalmau Portulas, Elena García-Martínez, Nuria Ribelles, A. Santaballa Bertran, E. Martínez de Dueñas, I Alvarez-Lopez, Susana Bezares
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Clinical & Translational Oncology
Universidad de Barcelona
Clinical & Translational Oncology
PurposeHormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b63a263cb82f360402dddafab187eefb
http://hdl.handle.net/2445/174389
http://hdl.handle.net/2445/174389
Autor:
Zsuzsanna Varga, Thomas Ruhstaller, Ulrike Perriard, Dirk Klingbiel, Tilman T. Rau, Jean-Christophe Tille, Beat Thuerlimann, Hanne Hawle, Qiyu Li, Wolfram Jochum
Publikováno v:
Varga, Zsuzsanna; Li, Qiyu; Jochum, Wolfram; Perriard, Ulrike; Rau, Tilman; Tille, Jean-Christoph; Hawle, Hanne; Klingbiel, Dirk; Thuerlimann, Beat; Ruhstaller, Thomas (2019). Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Scientific reports, 9(1), p. 13534. Springer Nature 10.1038/s41598-019-49638-4
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports, Vol. 9, No 1 (2019) P. 13534
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports, Vol. 9, No 1 (2019) P. 13534
Scientific Reports
The assessment of Ki-67 in early-stage breast cancer has become an important diagnostic tool in planning adjuvant therapy, particularly for the administration of additional chemotherapy to hormone-responsive patients. An accurate determination of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::509ed0eb6c511bb431eb561f8c240921
Autor:
Graham Ball, Jonathon Blake, Amanda Devaney, Aoife Lowery, Christophe Lemetre, Vladimir Benes, Sabine Schmidt, Roisin E McNeill, Nicola Miller, Pamela A Davoren, Michael J. Kerin
Publikováno v:
Breast Cancer Research : BCR
peer-reviewed Introduction Breast cancer is a heterogeneous disease encompassing a number of phenotypically diverse tumours. Expression levels of the oestrogen, progesterone and HER2/ neu receptors which characterize clinically distinct breast tumour
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d2ae9d83199bb46e19c5d330eaa7d0f
http://hdl.handle.net/10379/12508
http://hdl.handle.net/10379/12508
Autor:
I.A.M. Mandjes, Esther H. Lips, Bas B. Koolen, Lennart Mulder, Sjoerd Rodenhuis, Jelle Wesseling, L. Wessels, J. J. de Ronde
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment, 140(1), 63-71. Springer New York
Breast cancer research and treatment, 140(1), 63-71. Springer New York
Intrinsic subtypes are widely accepted for the classification of breast cancer. Lacking gene expression data, surrogate classifications based on immunohistochemistry (IHC) have been proposed. A recent St. Gallen consensus meeting recommends to use th
Publikováno v:
Cancer Immunology, Immunotherapy
To examine the relationship between cytotoxic T lymphocyte antigen 4 (CTLA-4) expression and breast cancer prognosis, CTLA-4 expression was immunohistochemically detected in paraffin-embedded specimens of primary tumors from 130 patients with breast
Autor:
Isabella Castellano, Fulvia Pedani, Paola Cassoni, Anna Sapino, Simona Osella-Abate, Michela Donadio, Mario Airoldi, Mauro Papotti, Sara Bustreo
Publikováno v:
Breast Cancer Research and Treatment
Although Ki67 index suffers from poor reproducibility, it is one of the most important prognostic markers used by oncologists to select the treatment of estrogen receptor (ER) positive breast cancer patients. In this study, we aim to establish the op
Autor:
Lisette Stork-Sloots, Paul Richards, Stephanie Akbari, Femke A. de Snoo, Mark A. Gittleman, Jennifer Beatty, Charles Nash, Laura A. Lee, Danielle Boselli, Angela Mislowsky, Mary Murray, James T. Symanowski, Peter D. Beitsch, Pat Whitworth, Paul L. Baron, James Pellicane
Publikováno v:
Annals of Surgical Oncology
Background The prospective Neoadjuvant Breast Symphony Trial (NBRST) study found that MammaPrint/BluePrint functional molecular subtype is superior to conventional immunohistochemistry/fluorescence in situ hybridization subtyping for predicting patho
Autor:
Hans-Peter Goertz, Amy Pugh, Juan Marcos Gonzalez, Vincent Antao, Christine Poulos, Eleftherios P. Mamounas
Publikováno v:
Annals of Surgical Oncology
Background This study aimed to assess the influence of disease- and patient-related factors on surgeons’ decisions to refer patients with early-stage breast cancer (EBC) for neoadjuvant systemic therapy (NST). Methods An online survey of United Sta
Autor:
Robert A. Goldschmidt, Lisette Stork-Sloots, Massimo Cristofanilli, Jelle Wesseling, Katharine Yao, Mary Turk, Femke De Snoo
Publikováno v:
Breast Cancer Research and Treatment
Combined use of MammaPrint and a molecular subtyping profile (BluePrint) identifies disease subgroups with marked differences in long-term outcome and response to neo-adjuvant therapy. The aim of this study was to evaluate the prognostic value of mol
Autor:
Paul E. Goss
Publikováno v:
Breast Cancer Research and Treatment
Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer. Third-generation aromatase inhibitors, such as letrozole, provide a new option for extended adjuvant hormonal therapy after 5